In vitro amplification of H-type atypical bovine spongiform encephalopathy by protein misfolding cyclic amplification by O'Connor, M.J. et al.
O'Connor, M.J. and Bishop, Keith and Workman, Robert 
G. and Maddison, Ben C. and Gough, Kevin C. (2017) In 
vitro amplification of H-type atypical bovine spongiform 
encephalopathy by protein misfolding cyclic 
amplification. Prion . ISSN 1933-690X 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/39831/8/Bovine%2019336896.2016.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the Creative Commons Attribution licence and may be 
reused according to the conditions of the licence.  For more details see: 
http://creativecommons.org/licenses/by/2.5/
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=kprn20
Download by: [University of Nottingham] Date: 10 February 2017, At: 03:37
Prion
ISSN: 1933-6896 (Print) 1933-690X (Online) Journal homepage: http://www.tandfonline.com/loi/kprn20
In vitro amplification of H-type atypical bovine
spongiform encephalopathy by protein misfolding
cyclic amplification
Matthew J. O'Connor, Keith Bishop, Robert G. Workman, Ben C. Maddison &
Kevin C. Gough
To cite this article: Matthew J. O'Connor, Keith Bishop, Robert G. Workman, Ben C. Maddison &
Kevin C. Gough (2017): In vitro amplification of H-type atypical bovine spongiform encephalopathy
by protein misfolding cyclic amplification, Prion, DOI: 10.1080/19336896.2016.1259051
To link to this article:  http://dx.doi.org/10.1080/19336896.2016.1259051
© 2017 The Author(s). Published with
license by Taylor & Francis© Matthew
J. O'Connor, Keith Bishop, Robert G.
Workman, Ben C. Maddison, and Kevin C.
Gough.Published online: 08 Feb 2017.
Submit your article to this journal 
Article views: 1
View related articles 
View Crossmark data
RESEARCH PAPER
In vitro amplification of H-type atypical bovine spongiform
encephalopathy by protein misfolding cyclic amplification
Matthew J. O‘Connora, Keith Bishopb, Robert G. Workmana, Ben C. Maddisonb, and
Kevin C. Gough a
aSchool of Veterinary Medicine and Science, The University of Nottingham, Sutton
Bonington Campus, College Road, Sutton Bonington, Leicestershire, UK;
bADAS UK, School of Veterinary Medicine and Science, The University of Nottingham,
Sutton Bonington Campus, College Road, Sutton Bonington, Leicestershire, UK
ABSTRACT. The in vitro amplification of prions by serial protein misfolding cyclic amplification has
been shown to detect PrPSc to levels at least as sensitive as rodent bioassay but in a fraction of the time.
Bovine spongiform encephalopathy is a zoonotic prion disease in cattle and has been shown to occur in
3 distinct forms, classical BSE (C-BSE) and 2 atypical BSE forms (L-BSE and H-BSE). Atypical
forms are usually detected in asymptomatic, older cattle and are suggested to be spontaneous forms of
the disease. Here, we show the development of a serial protein misfolding cyclic amplification method
for the detection of H-BSE. The assay could detect PrPSc from 3 distinct experimental isolates of H-
BSE, could detect PrPSc in as little as 1£10¡12 g of brain material and was highly specific.
Additionally, the product of serial protein misfolding cyclic amplification at all dilutions of seed
analyzed could be readily distinguished from L-BSE, which did not amplify, and C-BSE, which had
PrPSc with distinct protease K-resistance and protease K-resistant PrPSc molecular weights.
KEYWORDS. atypical prions, bovine spongiform encephalopathy, H-type BSE, PMCA
INTRODUCTION
Prion diseases, or transmissible spongiform
encephalopathies (TSEs), are progressive, fatal
diseases that affect a range of mammalian spe-
cies, including man. It is now widely accepted
that the central event in these diseases is the mis-
folding of the benign cellular prion protein
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(PrPC) into a disease-associated isoform
(PrPSc).1 Over a very protracted presymptomatic
phase, PrPSc converts host PrPC into the mis-
folded form and accumulates, particularly in the
central nervous system (CNS) tissues. This dis-
ease process leads to neurodegeneration, clinical
symptoms and death.
It is usual for TSEs to be host restricted
with the notable exception of bovine spongi-
form encephalopathy (BSE). BSE was first
described in cattle in the mid 1980s and led
to the BSE epidemic in cattle in the UK.
The BSE agent has also been identified as
causing disease in humans (variant Creutz-
feld Jakob disease, vCJD), exotic ungulates,
wild and domestic cats and goats. It is likely
that the BSE agent was transmitted to these
different host species via contaminated feed/
food. This unusually wide range of host spe-
cies for BSE would indicate that this form
of prion is relatively promiscuous and can
replicate within hosts having a diverse range
of PrPC primary sequences and concomitant
tertiary structures.
The molecular properties of the PrPSc gen-
erated during classical BSE infections (so-
called C-BSE) produces a protease-resistant
core with a very characteristic molecular
weight. C-BSE also produces consistent in
vivo pathology in bovines2 as well as upon
passage in rodent models even with BSE
from various host species.3 Two further
prion diseases have been identified in cattle
due to their divergence from the consistent
molecular and pathological traits of C-BSE,
namely L-type and H-type BSE. L-BSE (or
bovine amyloidotic spongiform encephalopa-
thy, BASE) was first identified by distinctive
amyloid plaques and PrPSc distribution
within the brain compare with C-BSE.4 L-
BSE also produces a PK-resistant PrPSc with
a lower molecular weight than C-BSE
together with a lower proportion of the
diglycosylated form.4 H-BSE produces a PK-
resistant PrPSc with a high molecular weight
compare with C-BSE,5,6,7 Both forms of the
disease were identified by active surveillance
in asymptomatic cattle and these animals
were usually 8 y or older leading to specula-
tion that these may be spontaneous diseases.8
Both atypical forms of BSE have been trans-
mitted to mice expressing the human PrPC gene
as well as non-human primates at rates exceed-
ing C-BSE, highlighting the possibility that
these could be zoonotic agents.9,10,11
Taken together, atypical BSE diseases are
potentially zoonotic agents that are usually
present in asymptomatic cattle. Therefore there
is a need for highly sensitive assays to detect
these forms of BSE, including during pre/sub-
clinical phases where prion may be present at
relatively low levels. Several reports have now
demonstrated that in vitro replication assays
may provide such tests. The protein misfolding
cyclic amplification (PMCA) method is based
on iterative rounds of sonication and incubation
to replicate very low levels of PrPSc seed within
PrPC substrate (usually a brain homogenate).12
The sonication step is thought to break prion
aggregates into smaller units that can efficiently
seed the conversion of PrPC into PrPSc during
the incubation period. Prion is amplified over
multiple (24-48) cycles of sonication/incuba-
tion (a round) and when serial PMCA (sPMCA)
is performed, for each subsequent round of
amplification the substrate is replenished by
diluting the PMCA products into fresh sub-
strate.13 The resulting amplified PK-resistant
PrPSc is then usually detected in western blots.
Quaking induced conversion (QuIC) is an alter-
native in vitro assay.14 This is based on the
ability of PrPSc to seed the conversion of a
recombinant PrP substrate into amyloid fibrils.
The method relies on iterative rounds of incu-
bation and vigorous shaking, fibrils form during
the incubation steps and are fragmented into
smaller seeds by shaking. The QuIC amyloid
products are usually monitored by thioflavin T
fluorescence in real time, although proteinase
K (PK) resistant products can also be analyzed
by western blotting.15
To date, PMCA has been used for the high
sensitivity detection of L-BSE derived from
experimentally infected macaques although the
products were not distinguished from other
types of BSE.16 QuIC has also been used to
amplify both L-BSE and H-BSE from infected
cattle. However, it was not possible to distin-
guish the BSE types when present at relatively
low concentrations.15
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Here, we have used sPMCA to demonstrate
the very high sensitivity detection of H-BSE
that can readily distinguish H-BSE from
L-BSE or C-BSE regardless of the PrPSc seed
concentration.
RESULTS
The amplification of atypical H-BSE prions
by sPMCA and subsequent analysis of the
products was performed by varying up to 4 con-
ditions: the source of substrate (including PrPC
primary sequence), the sonication duration, the
presence or absence of Teflon beads and the
concentration of PK used to digest sPMCA
products (Table 1). The first optimisation step
looked at a single sonication time (40s) in the
absence of Teflon beads using 4 substrates
derived from bovine, ovine AHQ/AHQ (corre-
sponding to codons 136, 151, and 170 in the
PRNP gene respectively), ovine ARQ/ARQ
and ovine VRQ/VRQ brains. Out of 2 replicate
analyses for each substrate, only a single
reaction with the bovine substrate gave detect-
able PrPSc triplet (Fig. 1A). Repeat analysis of
these conditions with bovine substrate demon-
strated that all 5 replicates gave low but detect-
able levels of PrPSc product (Fig. 1B). When
sonication times of 30, and 20 s were used with
bovine substrate, 30 s gave low levels of PrPSc
in all 5 replicates and 20 s gave low levels of
PrPSc in 2 out of 5 replicates. In the presence of
Teflon beads with bovine substrate, all 3 soni-
cation times failed to produce any PrPSc. The
products of amplification of H-BSE in bovine
substrate with all sonication times were
digested with 5, 10 or 50 mg/ml. While weak
PrPSc signals were detected on western blots
with the highest protease concentration, all of
these positive amplifications yielded higher
levels of defined PrPSc triplet at the lower 2
concentrations over background undigested PrP
(Fig. 1B and data not shown). It was noted that
at these lower protease concentrations, a single
band for substrate PrPC that was between the
molecular weights for di- and mono-glycosy-
lated PK-resistant PrPSc could be observed, as
TABLE 1. Optimisation of the replication of H-BSE in sPMCA.
Sonication time (s)
Presence of
Teflon beads Substrate
[PK]
(mg/ml)
Amplification
effciency1
Phase 1: optimisation of substrate
40 ¡ bovine 50 1/22
40 ¡ ovine AHQ 50 0/2
40 ¡ ovine ARQ 50 0/2
40 ¡ ovine VRQ 50 0/2
Phase 2: optimisation of sonication time
40 ¡ bovine 50 5/52
30 ¡ bovine 50 5/52
20 ¡ bovine 50 2/52
Phase 3: presence of Teflon beads
40 C bovine 50 0/5
30 C bovine 50 0/5
20 C bovine 50 0/5
Phase 4: digestion of products with different protease
concentrations
40 ¡ bovine 10 5/5
5 5/5
30 ¡ bovine 10 5/5
5 5/5
Phase 5: specificity of the optimised conditions
40 ¡ bovine 10 0/203
1Number of amplification reactions producing protease-resistant PrPSc/total number of reactions
2These were relatively weak signals on western blots
3Control sPMCA reactions not containing any PrPSc seed
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previously reported.17 The optimal conditions:
bovine substrate, 40 s sonication times without
Teflon beads and 10 mg/ml PK digestion of
sPMCA products were used in all subsequent
experiments. Three experimental isolates of H-
BSE were available for analysis and all 3
amplified under these sPMCA conditions when
analyzing 10 ml of a 10¡2 dilution of brain
homogenate (equivalent to 100 mg of brain
material) with 5 out of 5 replicates amplified
for each (Fig. 1B and C). Similar amplification
of C-BSE consistently yielded PrPSc but 3 iso-
lates of L-BSE were not amplified under these
conditions (data not shown). Dilution series of
H-BSE and C-BSE were analyzed (Table 2,
Fig. 2). For C-BSE, 2 samples were analyzed
and the limit of detection of PrPSc was when
analyzing a 10¡6 or 10¡7 dilution of brain
(equivalent to 10 or 1 ng of brain material). For
H-BSE the limit of detection was at least as
FIGURE 1. Amplification of H-BSE by sPMCA. A single isolate of H-BSE (SE2053/0089) was
amplified over 5 d by sPMCA in duplicate in ovine (PRNP genotypes AHQ, ARQ or VRQ) or bovine
(bov) substrate and products digested with 50 mg/ml PK (A; * weak signal detected for PrPSc trip-
let). The same H-BSE isolate was amplified in 5 replicate reactions using bovine substrate and
products after 5 d of amplification were digested with 50, 10 or 5 mg/ml PK (B; * weak signal
detected for PrPSc triplet,C reaction containing H-BSE seed, - reaction not containing any H-BSE
seed). Two further isolates of H-BSE were amplified in 5 replicates in bovine substrate and prod-
ucts digested with 10 mg/ml PK (C). All sPMCA reactions used 40 s sonication durations and
digested products were analyzed on western blots using anti-PrP antibody SHa31. Molecular
weight markers are indicated.
4 M. J. O’Connor et al.
sensitive, PrPSc could be detected in the brain
of 2 experimental isolates at 10¡7 or 10¡10
dilutions (equivalent to 1 ng or 1 pg of brain
material). The analysis of 20 replicates that
contained no PrPSc seed did not produce any
detectable PrPSc triplet, only a single undi-
gested PrPC band as described above (data not
shown). It was clearly evident that amplifica-
tion products from H-BSE seed were
distinguishable from those from C-BSE seed
across the range of seed concentrations used.
The H-BSE and C-BSE products of sPMCA
could be distinguished due to their PK-resis-
tance by determining the ratio of PrPSc signal
produced when digesting samples with 10 or
50 mg/ml PK (p D 0.008 using a 2-tailed,
unpaired Student’s t test; Fig. 3). The H-BSE
and C-BSE products of amplification also
TABLE 2. Limit of detection of H-BSE amplification by sPMCA.
Brain tissue dilutiona H-BSE SE2053/0089 H-BSE SE1868/0011 C-BSE pool 1b C-BSE SE1762/0013
10¡2 ND 2/2 2/2 2/2
10¡3 2/2 2/2 2/2 2/2
10¡4 2/2 2/2 1/2 2/2
10¡5 2/2 2/2 2/2 1/2
10¡6 2/2 2/2 1/2 1/2
10¡7 2/2 2/2 1/2 0/2
10¡8 2/2 0/2 0/2 0/2
10¡9 2/2 0/2 0/2 0/2
10¡10 1/2 ND ND ND
10¡11 0/2 ND ND ND
10¡12 0/2 ND ND ND
a10¡2 dilution contains 100 mg of brain tissue and is the equivalent of using 1 ml of a 10% (w/v) brain homogenate as the seed in a 100 ml
sPMCA reaction.
bThe sample was a pool of 10 bovine BSE isolates mixed in equal volumes
FIGURE 2. Estimation of the limit of detection of H-BSE by sPMCA. H-BSE isolates SE2053/0089
(A) and SE1868/0011 (B) were amplified by sPMCA using bovine substrate and 40 s sonication
times over 5 d. The dilution of brain material used to seed sPMCA reactions is indicated. Products
of amplification were digested with 10 mg/ml PK before western blot analysis and probing with anti-
PrP antibody SHa31. Molecular weight markers are indicated.
AMPLIFICATION OF H-BSE BY PMCA 5
differed in the molecular weight of the ungly-
cosylated PrPSc band (p<0.0001 using a 2
tailed, unpaired Student’s t test; Fig. 4C) which
was readily identified by the level of binding to
the antibody P4 (ratio values analyzed in a 2
tailed, unpaired Student’s t test p D 0.0046;
Fig. 4A and B).
DISCUSSION
The detection of PrPSc is a surrogate marker
for prion diseases and has formed the basis of
veterinary screening tests for ruminants. C-
BSE in cattle is the only zoonotic prion disease
recorded to date and as such the testing of food
production animals is driven by the require-
ment to detect the C-BSE agent and minimize
its risk to human health. Screening tests applied
to cattle use post mortem brain tissue samples
from which to detect PrPSc and rely on the
presence of relatively high levels of PrPSc in
the caudal region of the brainstem. Such tests
may not be sensitive enough to detect PrPSc
present at low levels during relatively early
stages of disease incubation. When considering
the atypical L-BSE and H-BSE diseases of cat-
tle, they have been assessed in both non-human
primate and transgenic mouse bioassays (with
mice transgenic for human PRNP) and both
model systems indicate that H-BSE and L-BSE
may have increased zoonotic potential compare
with C-BSE.9,10,11 The detection of all types of
BSE is therefore of significant importance.
Both L-BSE and H-BSE have been identified in
mainly asymptomatic animals of a relatively
advanced age, »12 y on average18 compare
with the estimated incubation period for cattle
naturally infected with C-BSE, which is 5.0–
5.5 y.19,20 It has been suggested that atypical
BSE types may be spontaneous diseases, there-
fore explaining the detection of PrPSc in mainly
FIGURE 3. Differentiation of amplified H-BSE and C-BSE by distinct protease resistance. H-BSE
(SE2053/0089) and C-BSE (pool-1) samples were each amplified by sPMCA using bovine sub-
strate and 40 s sonication times over 5 d. Products of amplification were digested with 50 or 10 mg/
ml PK (as indicated) before western blot analysis and probing with anti-PrP antibody SHa31 (A).
The spikes used for sPMCA of H-BSE were dilutions at 10¡2 (100 mg of brain material, H1) or 10¡7
(1 ng of brain material, H2) of brain material. The spikes used for sPMCA of C-BSE were dilutions
at 10¡2 (100 mg of brain material, C1) or 10¡5 (100 ng of brain material, H2) of brain material. The
ratio of PrPSc western blot signals for sPMCA products at the 2 PK concentrations are shown when
analyzing 2 H-BSE isolates (SE2053/0089 and SE1868/0011) and 2 C-BSE samples (pool-1 and
SE1762/0013) at high and low spike concentrations (B). Molecular weight markers are indicated.
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older animals.8 The presence of relatively low
levels of PrPSc in atypical BSE cases, compared
with C-BSE, is likely for most age groups of
cattle. Therefore the detection of PrPSc by con-
ventional biochemical tests used in routine sur-
veillance would be more challenging in
atypical BSE cases. Given the high zoonotic
potential of atypical BSE types it is important
to develop very high sensitivity tests to detect
the concomitant PrPSc in routinely sampled tis-
sue. Such tests would not only be applicable to
routine surveillance testing but also to deter-
mine in vivo dissemination of atypical prions to
inform risk assessments of bovine material
entering the human food chain. To this end,
several studies have looked to develop in vitro
prion amplification assays to detect very low
levels of atypical BSE prions. Murayama and
coworkers used wild type mouse brain as
sPMCA substrate supplemented with a cocktail
of polyanions (polyadenylic acid salt (Poly-A),
heparin and sodium polyphosphate) and L-argi-
nine ethylester.16 The method included sPMCA
amplifications over 280 hours and could detect
L-BSE down to a 10¡10 dilution of brain
homogenate. The method could detect L-BSE
in cerebrospinal fluid, saliva, urine and plasma
from macaques experimentally infected with L
BSE. Prion was detected in saliva and urine in
preclinical samples from 1 of 2 infected ani-
mals; and in CSF samples taken preclinical in
both animals.
Several studies have looked to use QuIC to
amplify both L-BSE and H-BSE and have uti-
lised recombinant hamster, sheep, human and
bank vole PrP as substrates.15,21,22
Human and hamster PrP consisting of resi-
dues 23–231 and hamster PrP residues 90–231
were found to only amplify L-BSE but not C-
BSE and could detect L-BSE down to 10¡6 to
10¡7 dilutions of brain homogenate, which
they report is at least as sensitive as mouse bio-
assay21,22 and approximately 4 orders of mag-
nitude more sensitive than commercial
immunoassays.15 Using bank vole recombinant
PrP as substrate allowed the amplification of H-
, L- and C-BSE. H-BSE could be detected
down to 10¡8 to 10¡9 dilution of brain homoge-
nate and H-BSE and L-BSE could be detected
in the CSF from clinically affected cows.15
FIGURE 4. Differentiation of amplified H-BSE and C-BSE by distinct PK cleavage sites. Two sam-
ples each of H-BSE and C-BSE samples were amplified by sPMCA using bovine substrate and
40 s sonication times over 5 d. Products of amplification were digested with 10 mg/ml PK before
western blot analysis and probing with anti-PrP antibody SHa31 or P4 (A). The spikes used for
sPMCA of H-BSE were dilutions at 10¡2 (100 mg of brain material, H1) or 10¡7 (1 ng of brain mate-
rial, H2) of brain material. The spikes used for sPMCA of C-BSE were dilutions at 10¡2 (100 mg of
brain material, C1) or 10¡5 (100 ng of brain material, H2) of brain material. The ratio of PrPSc west-
ern blot signals for sPMCA products detected by the 2 antibodies are shown (B). The molecular
weight of the unglycosylated PrPSc band for each sample is also shown (C). Molecular weight
markers are indicated.
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Masujin and coworkers propose a scheme to
use QuIC to distinguish H- L- and C-BSE
infections.15 The proposed method analyses
samples simultaneously in bank vole and ovine
ARR substrate on the same QuIC plate. C-BSE
is only amplified in bank vole substrate and, for
L-BSE and H-BSE, the comparative lag phases
of amplification are compared for each sub-
strate, with L-BSE having a relatively shorter
lag phase compare with H-BSE in ARR sub-
strate, and the reverse being the case in bank
vole substrate. The test samples are run along-
side positive control samples of each BSE type
for comparison. The method was shown to be
able to distinguish BSE types for dilutions
between 10¡3 and 10¡5 of brain homogenate
from clinically affected cows but could not dif-
ferentiate BSE types at lower concentrations.
In summary, in vitro amplification methods
have been established for L-BSE and H-BSE
prions with higher sensitivity than transgenic
mouse bioassay (»10¡5 dilution of brain
homogenate). However, at present sPMCA can
be used to only detect L-BSE and while the
QuIC method can detect both L- and H-BSE, at
lower levels of prion (< 10¡5 dilution of brain
homogenate) the BSE types cannot be
distinguished.
Here, we developed a sPMCA method to
detect H-BSE. The most optimal conditions
used 40s sonication durations and bovine PrPC
substrate. The assay amplified all isolates of H-
BSE and C-BSE tested and could detect H-BSE
down to 10¡7 and 10¡10 dilution of brain
homogenate. L-BSE was not amplified under
the conditions used and the H-BSE and C-BSE
products of amplification could be readily dis-
tinguished by the molecular weight of their
unglycosylated PrP product or by the relative
PK-resistance of the PrPSc. The molecular
weight differences between PrPSc from H-BSE
and C-BSE is a trait seen in both the brain
derived PrPSc and also the sPMCA products. It
has also been previously reported that H-BSE
has a lower PK resistance than C-BSE5 and this
trait seems to be exaggerated in the sPMCA
products. Importantly, the ability to identify H-
BSE in sPMCA products was maintained
across all of the dilution ranges of seed ana-
lyzed (down to 10¡7 dilution of brain
homogenate) indicating that the assay can
detect and strain type very low levels of H-type
BSE.
The present study describes a sPMCA
method for the amplification of H-BSE PrPSc
that has very high sensitivity and can distin-
guish H-BSE from other BSE types. Given
these properties, the assay has the potential to
describe the in vivo dissemination of H-BSE
PrPSc in infected animals across the time-
course of infection, in order to define tissues
that harbour H-BSE prions.
METHODS
Samples
All brain samples from BSE-affected ani-
mals were taken from the hindbrain and were
provided from the Animal and Plant Health
Agency (APHA) biological archive. H-BSE
and L-BSE samples were from experimentally
infected animals, C-BSE samples were from
natural infections. Three samples each of H-
BSE, L-BSE and C-BSE were available for use
in the study: H-BSE isolates were SE2053/
0089, SE1868/0010 and SE1868/0011; L-BSE
isolates were SE1868/0008, SE1868/0009 and
SE2053/0106; C-BSE samples were SE1762/
0013, SE2053/0055 and BSE pool 1. The latter
was a pool of 10 bovine BSE isolates mixed in
equal volumes: PG00091/04, PG00034/04,
PG01184/02, PG01257/02, PG01412/02,
PG00345/03, PG00365/03, PG00449/03,
PG00487/03 and PG00572/03. Samples were
prepared as 10% (w/v) brain homogenates as
previously described.23 Brain samples from
TSE-free animals were provided by the APHA.
sPMCA
Substrate was prepared from a single Hol-
stein Friesian cow, or sheep with PRNP geno-
types AHQ/AHQ (corresponding to codons
136, 151, and 170, respectively), VRQ/VRQ or
ARQ/ARQ as previously described.24 sPMCA
was performed basically as previously
described23 but with some modifications. Each
sPMCA reaction was set up by adding the test
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sample (10 ml of a dilution of brain homoge-
nate) into substrate to a final volume of 100 ml.
Samples were sealed within 0.2 ml PCR tubes
and then placed into an ultrasonicating water
bath (model 4000; Misonix) at 37C. Sonica-
tions were performed for 20, 30 or 40 s at
200 W and repeated once every 30 min for
24 h (one sPMCA round), after which, the sam-
ples were diluted 1 in 3 with fresh substrate
brain homogenate to a final volume of 100 ml,
and the samples were subjected to a total of 5
rounds of sPMCA. sPMCA was also performed
in the presence or absence of 3 Teflon beads
per tube.25
Western Blots
Samples were digested with PK and then
analyzed by western blotting using the mono-
clonal antibodies SHa31 or P4 as described pre-
viously.23 Briefly, samples were digested with
5, 10 or 50 mg/ml PK in the presence of
0.045% (w/v) SDS for 1 h at 37C. Samples
were boiled in 1x NuPAGE SDS-PAGE sample
buffer for 5 min, and then an equivalent to 5 ml
of the sPMCA reaction products was electro-
phoresed on 12% (w/v) polyacrylamide gels
(precast NuPAGE SDS-PAGE Bis-Tris; Invi-
trogen). Samples were transferred to polyviny-
lidene difluoride membranes by electroblotting
and then blocked in 3% (w/v) skimmed milk-
PBS. Blots were probed with SHa31 or P4
monoclonal antibody at a dilution of 1/80,000
for SHa31(Cayman Chemicals) or 1/1,000 for
P4 (R-Biopharm) in 0.5% (w/v) skimmed milk-
PBS. After washing, the blots were probed
using a secondary goat anti-mouse horseradish
peroxidase (HRP) conjugate at a 1/20,000 dilu-
tion (Dako). Blots were visualized using an
HRP chemiluminescent substrate (Geneflow)
and a Photek imaging system.
For densitometry, gel images were measured
with ImageJ software and the lane pixel densi-
ties were plotted, the signal maxima for each
band was used (molecular weight analysis) or
the total areas corresponding to the band peaks
were defined and the background for each lane
was subtracted (all other analysis). When calcu-
lating molecular weights, the migration
distance of proteins through the SDS-PAGE
gel was measured and a standard curve gener-
ated using the migration distances of the 60,
50, 40, 30 and 20 kDa molecular mass stand-
ards (NuPAGE Magicmark, Invitrogen). Using
linear regression analysis, the molecular weight
of unglycosylated PrPSc was then calculated
from the curves using Graphpad prism soft-
ware. The SHa31/P4 ratio for a sample was cal-
culated as the ratio of the western blot signals
produced by samples when probed with SHa31
and P4 monoclonal antibodies on 2 separate
blots. This is a measure of the presence of the
P4 epitope within PrPSc after PK digestion, the
epitope is present at relatively high levels in
ovine scrapie isolates and H-BSE, but at much
lower levels in C-BSE and L-BSE isolates.26
The ratio of PK-resistant PrPSc when samples
were digested at 10 and 50 mg/ml PK were
determined using densitometry to determine
total PrPSc signals as described above.
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